Casonato A, Bertomoro A, Pontara E, Dannhauser D, Lazzaro A R, Girolami A
University of Padua Medical School, Institute of Medical Semeiotics, Italy.
J Clin Pathol. 1994 Jul;47(7):625-30. doi: 10.1136/jcp.47.7.625.
To clarify the mechanisms involved in the development of EDTA dependent pseudothrombocytopenia, particularly the platelet receptors.
Platelets were measured in 33 patients with pseudothrombocytopenia, using different anticoagulants to collect blood samples (direct test). The results were compared with the counts obtained by adding patients' serum or immunoglobulins to normal blood samples (indirect test). The role of platelet function was explored using ASA, PGE1, and apyrase as platelet inhibitors. The contribution of platelet receptor/s was investigated using antigens to gpIb-IX and gpIIb-IIIa monoclonal antibodies. Immunoglobulin class was estimated by the ability of IgG, IgA, and IgM antibodies to prevent platelet clumping.
Agglutinating antibodies were IgA in 40%, IgG in 30%, and IgM in 10% of patients studied. Both patients' serum and immunoglobulins induced platelet clumping in normal samples anticoagulated with EDTA (indirect test). This was prevented by incubation of blood samples at 37 degrees C and almost completely inhibited by the platelet inhibitors ASA, PGE1, and apyrase. Pseudothrombocytopenia was also entirely prevented by an antigen to gpIIb-IIIa monoclonal antibody that recognises fibrinogen and the von Willebrand factor binding site. Pseudothrombocytopenia was almost completely abolished after the addition of RGD peptide, the recognition sequence of cytoadhesive proteins.
These findings suggest that EDTA dependent pseudothrombocytopenia is caused by agglutinating antibodies that recognise cytoadhesive receptors on platelet gpIIb-IIIa and that an efficient platelet metabolism is required.
阐明乙二胺四乙酸(EDTA)依赖性假性血小板减少症发生发展的机制,尤其是血小板受体。
对33例假性血小板减少症患者进行血小板检测,使用不同抗凝剂采集血样(直接试验)。将结果与通过向正常血样中添加患者血清或免疫球蛋白所获得的计数结果进行比较(间接试验)。使用阿司匹林(ASA)、前列腺素E1(PGE1)和腺苷双磷酸酶作为血小板抑制剂来探究血小板功能的作用。使用针对糖蛋白Ib-IX(gpIb-IX)和糖蛋白IIb-IIIa(gpIIb-IIIa)单克隆抗体的抗原研究血小板受体的作用。通过IgG、IgA和IgM抗体预防血小板聚集的能力来评估免疫球蛋白类别。
在所研究的患者中,40%的患者凝集抗体为IgA,30%为IgG,10%为IgM。患者的血清和免疫球蛋白均可在EDTA抗凝的正常样本中诱导血小板聚集(间接试验)。将血样在37℃孵育可预防这种情况,而血小板抑制剂ASA、PGE1和腺苷双磷酸酶几乎可完全抑制。识别纤维蛋白原和血管性血友病因子结合位点的针对gpIIb-IIIa单克隆抗体的抗原也可完全预防假性血小板减少症。添加细胞粘附蛋白的识别序列RGD肽后,假性血小板减少症几乎完全消失。
这些发现表明,EDTA依赖性假性血小板减少症是由识别血小板gpIIb-IIIa上细胞粘附受体的凝集抗体引起的,并且需要有效的血小板代谢。